Ranbaxy's Patent Litigations in the United States
|
|
ICMR HOME | Case Studies Collection
To download Ranbaxy's Patent Litigations in the United States case study
(Case Code: ECON015) click on the button below, and select the case from the list of available cases:
» Economics
Case Studies
» Case Studies Collection
» ICMR Home
» Short Cases Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
Case Details: |
Price: |
| Case Code |
: |
ECON015 |
For delivery in electronic format: Rs. 300;
For delivery through courier (within India): Rs. 300 + Shipping & Handling Charges extra
ThemesCorporate Social Responsibility
Themes- |
| Case Length |
: |
14 Pages |
| Period |
: |
1993-2005 |
| Pub Date |
: |
2006 |
| Teaching Note |
: |
Not Available |
| Organization |
: |
Ranbaxy
Laboratories Limited |
| Industryy |
: |
Pharmaceutical |
| Countries
|
: |
USA |
Abstract:
|
The case focuses on Ranbaxy Laboratories Limited's patent litigations in the US.
It elaborates on the factors that led to the company's global expansion,
focusing specifically on the US market. The case discuses in detail Ranbaxy's
approach to the US market and also discusses its initial successes. It also
looks at the US pharmaceutical industry and the patent system in the US in
detail. The Hatch-Waxman Act of 1984 and its significant impact on the generics
pharma industry in the US are also explained. The case discusses the problems
faced by the generics players in the US in the extremely competitive generics
market and the effect of increasing patent litigation costs involved in
challenging patent holders.
|
|
It ends with a note on Ranbaxy's challenges
in meeting its target of $ 2 billion for the year 2007..
Issues:
» Growth strategy of a pharmaceutical company in the international market
» Benefits and downside of adopting of an inorganic growth strategy in an
international market
» Nature and scope of the US pharmaceutical industry
» Legal and regulatory environment in the US
» How patent litigations can be the strategy of choice of generics players for
revenue growth
» Impact of patent litigations on generics players as well as on patent holding
companies
Contents:
Keywords:
Ranbaxy Laboratories Limited, Pfizer, Lipitor, Teva
Pharmaceuticals USA Inc., Glaxo Wellcome, Patent Litigations, Drug Price Control
Order, Indian Patent Act of 1970, Ranbaxy Pharmaceuticals Inc., Food and Drug
Administration (FDA), Generics, Patent and Trademark Office, Pharmaceutical
Industry, Hatch-Waxman Act, Abbreviated New Drug Application, Paragraph IV (Para
IV) certification, Eli Lilly, Cefaclor, Patent, Dr. Reddy's Laboratories
Ranbaxy's Patent Litigations in the United States - Next Page>>
|
|
